2020 The World's Top 50 Pharmaceutical Companies and their best-selling drugs.

Recently, the U.S. "Pharmaceutical Managers" magazine published its 2020 top 50 pharmaceutical companies. The list is based on the global sales of prescription drugs for each pharmaceutical company in 2019, and is a more visual representation of the strength of each pharmaceutical business.
Pharmaceutical Manager has launched The Top 50 20 times in a row. 2020 TOP10 list and ranking has changed a lot, Roche first topped the top, Shi Guibao after 10 years to enter the top 10, Takeda first into the top 10. Roche topped the list for the first time with $48.247 billion in sales, up 8.3 percent from a year earlier, ending Pfizer's four-year dominance. Novartis' sales rose 6.0 percent, rising 1 places to No. 2, while Pfizer's sales fell 3.6 percent to No. Merck's sales rose 9.5 percent, rising 1 place to 4th place. Squip completed its acquisition of New Base, with consolidated sales of $40.689 billion, rising from 11th place last year to 5th place. Johnson and Johnson's sales rose slightly by 3.3%, but its ranking fell from 4th to 6th. The top six have more than $40 billion in sales, compared with the top three last year. Sanofi, AbbVie and GlaxoSmithKline all dropped 1 st at No. 7, 8 and 9. Takeda completed its acquisition of Shire, with consolidated sales of $29.247 billion, rising from 16th last year to 10th place.
in absolute terms of research and development spending, Roche of Switzerland ranked first in research and development spending at $10.293 billion, up 5% from $9,803 million in 2019, the first time in nearly a decade that a pharmaceutical company has spent more than $10 billion a year on research and development. Squip merged with the new base to be second at $9.381 billion, while Johnson and Johnson ranked third at $8.834 billion, up 4.6 percent from $8.446 billion in 2019. Merck ranked fourth at $8.73 0 billion, up 10.4 percent from $7.908 billion in 2019. Novartis of Switzerland ranked fifth at $8.386 billion, an increase of $232 million over 2019. Pfizer ranked sixth at $7,988 million, up just $226 million from 2019. Sanofi ranked 7th at $6,071 million, down 2.5 percent from $6.227 billion in 2019. The Top 10 list only included a year-on-year decline in Sanofi and AbbVie's research and development spending. The statistics of research and development expenditure are generally the total research and development expenses of the company's entire business, without distinguishing between the research and development costs of prescription drugs, OTCs and consumer health care products, medical devices, etc. Some companies' research and development costs have significantly changed compared to their 2019 costs, which are estimated to be related to their financial accounting and accounting processing. Sales growth was achieved at 40 of the
50 companies (five new companies should have grown to make the list), with the largest increases coming from squiplot and Japan's Takeda, which grew by $19.108 billion and $11.82 billion, respectively, and the 10 companies saw sales decline by $2.032 billion, respectively. Thirty of the top 50 companies have increased their research and development investment, 13 have reduced their investment in research and development, 2 have no research and development investment data, and 5 new entrants have no comparable data. From each company's top three best-selling drugs can be deduced that some companies are still more focused on a treatment area, such as Roche's main products to treat cancer, Gilead focus on viral infections, Novo norNord focus on diabetes, Lilly focus on diabetes, Baijian focus on multiple sclerosis, Futai Pharmaceuticals focus on cystic fibrosis, more enterprises such as Ali brother, regenerative yuan and Baijian, Futai Pharmaceuticals and other rare diseases in the field of rare disease.
the global prescription drug king is still AbbVie's Semame, with sales of $19.169 billion in 2020, down 3.85 percent from $19.936 billion in 2019, accounting for 59.2 percent of AbbVie's global prescription drug sales and 3 percent from 62.2 percent in 2019. AbbVie's Sioe, a heavyweight product, is at risk of a sharp drop in sales once the product's patent expires, although it accounts for a decline in sales but still nearly 60 percent. In the U.S. market, although the core patent for Siomer expired in 2016, under the settlement agreement, AbbVie successfully postponed the threat of biosimilars until January 2023, and Sumer was happy to lose patent protection in the European market on October 16, 2018. At least five of the EU's EMA-approved Symelo biosimilars have been approved, and the release of generics will undoubtedly affect Supael's sales in Europe, while AbbVie has fought back in the first place to offer discounted Susmerto to maintain market share, so Supler's sales have fallen in 2019. In second place is Merck's Coreida (Paboli-L1), the world's second approved PD-1/PD-L1 drug, but its sales were $11,084 million, up 56.4 percent from $7,171 million in 2019, far outpacing the world's first-listed Squire Opdivo, which has sales of $7.204 billion, ranking 5th in 2020 and growing by 7.00 percent in 2020. The third-highest number of prescription drugs was reliono's Reillymed (in-the-form) at $10.97 0 billion, up 13.3 percent from $9.685 billion in 2019. In fourth place is Squibb's Aleto (Apixaban), which has sales of $7.929 billion and sales growth of 23.2 percent, and has become the leading market leader in the oral anticoagulant market in the United States. At number six is Roche's Avetin (Bevalbitin) $7.118 billion, which replaces Heseltine (quorbead synth) as Roche's number one best-selling drug, and hersed in declining sales because its patents have expired and are being competitive with Biosimilars of Celltrion, Teva, Pfizer and Mylan.
since June 2019, the global biopharmaceutical sector has been trading heavily, maintaining its early 2019 momentum. In June 2019, AbbVie announced its $63 billion acquisition of Aer Lingus, a deal that was officially completed on May 8, 2020, that allowed AbbVie to acquire Al-Jian's medical product, And another product, the boureic acid injection filler, Joarden, which is global medicine. The combined company will cover areas of immunity, blood cancer, medical beauty, neurology, women's health, ophthalmology and virology, so in next year's top 50, AbbVie is expected to move from its current no.8 to the global TOP5 list, while Algen (18th) will disappear. On June 10, 2019, Merck announced the acquisition of unlisted biopharmaceutical company Tilos Therapeutics, which develops cancer, fibrosis and autoimmune disease therapy, for up to $773 million. In July 2019, Pfizer completed its $11.4 billion acquisition of Array BioPharma, a cancer-focused drug focused on the development of targeted small molecule drugs, with a portfolio that includes non-removable or metastatic melanoma combination therapy that is already available in the United States to treat BRAF mutations, an encorafenib-binimetinib, a range of potential "best-in-class" and "first-class" drugs. On July 15, 2019, Bollinger Ingham announced the acquisition of a full stake in AMAL Therapeutics for a total value of 325 million euros, with AMAL focusing on cancer immunotherapy and developing a series of "first-in" based on its own technology platform KISIMA -Class" therapeutic cancer vaccine, AMAL's main vaccine product ATP128 is currently undergoing research for patients with stage IV colorectal cancer, and Bollinger Ingehan plans to combine the company's cancer immune portfolio with AMAL's proprietary KISIMA immune platform to develop new treatments. On November 16, 2019, Roche announced that it would acquire Promedior for $1.39 billion, which will give it full interest in all of its anti-fibrosis products, including the PRM-151, which is a Recombinant endogenous pregencyntin 2 (pentraxin-2) has significantly improved lung function in patients with iexclusiveidal pulmonary fibrosis (IPF), after the FDA awarded PRM-151 breakthrough therapy. In December 2019, Astellas announced that it will buy gene therapy company Audentes Therapeutics for $3 billion, and the deal is expected to be completed in 2020, with Audentes' flagship product, AT132, for the treatment of the rare neuromuscular disease, X chromosome chain myocardial disease, which is currently in Phase 2 clinical trials and has been awarded by the FDA for regenerative medicine and advanced therapies, fast-track qualification, and orphan-status drugs. In December 2019, Sanofi announced plans to buy Synthorx, a biotech company that develops new protein therapies using synthetic biology technology, to develop a molecule THOR-707 that can be combined with human-effect T-cells and natural killer cells to treat cancer in conjunction with the current pipeline of cancer drugs and new immunomodulators, promising to become the next generation of immunotherapy. As can be seen, companies want to diversify new areas and invest more research and development resources to gain better pricing power, such as in the treatment market for rare diseases. According to the EP report, rare and orphan drugs will account for a fifth of worldwide prescription drug sales by 2024, costing a total of $242 billion. These mergers will affect the ranking of the top 50 in 2020.
January 2020, Novartis completed a $9.7 billion acquisition of The Medicines Company, acquiring its heart drug Inclisiran, which is expected to be a front-line cholesterol-lowering treatment. On January 12, 2020, Lilly announced a $1.1 billion acquisition of Dermira Inc., a company dedicated to developing chronic skin disease therapies, to acquire its innovative human-derived anti-albino 13 (IL-13) monoclonal antibody lebrikizumab, and a dermatology treatment called Qbreza (gcopylyrriumon), which has been approved by the U.S. FDA, to enhance its pipeline for immunology research. In early March 2020, Gilead acquired 4.9 billion CD47 leader Forty Seven, a core product of the Cd47's human-sourced lgG4 monoantinoMagm, in addition to two currently in the research product FSI-174 And FSI-189, where fSI-189 is also blocking the CD47-SIRP alpha this path, but the relationship between SIRP alpha-Magrolimab and FSI-189, similar to the pD-1 and PD-L1 relationship. On June 7, 2020, industry rumors that AstraZeneca planned to buy Gilead for $93 billion were denied, but the outflow is usually not empty and it remains to be seen whether AstraZeneca and Gilead will eventually merge into another TOP5-level pharmaceutical giant.
in the case of generics, on November 12, 2019, Pfizer and Mylan announced that the name of the new company, which will be merged with Pfizer subsidiaries Pujols and Mylan, will be Viatris. Puqiang is Pfizer's patent-expired brand and generics business, which brings together 20 well-known brands such as Lipto, Ciering and Wan Aico. Mylan (21st) is one of the world's leading generics companies, surpassing Teva (22nd) in 2020 to become the world's leading generic drug manufacturer, offering a growing portfolio of more than 7,500 products worldwide, covering a wide range of diseases such as central nervous system and anesthesia, infectious diseases and cardiovascular diseases. The deal is expected to close in mid-2020, when the new company Viatris will become the world's number one generic, and next year's top 50 will see Viatris likely to be among the world's TOP15 drug makers, while Mylan (21st) will disappear.
the 50th-ranked Arabindo sales were $2.787 billion in 2020, compared with $2,461 million for 50-year-old Pfizer in 2019. With an increase of $326 million, the threshold exceeded $2.7 billion for the first time, and the threshold for the top 50 has risen year after year, from $2.2 billion to $2.4 billion to $2.7 billion, reflecting the rapid growth of more pharmaceutical companies in one way.
in the top 50, compared with the 2019 research and development cost investment, some enterprises in 2020 have normal fluctuations, such as ShiGuibao after the merger of the new base increased by 82.8%, research and development investment rate of 23.0%. After Takeda merged with Shire, it grew by 47.1% and the research and development investment rate was 15.2%. Some companies have shown significant growth, such as China Hengrui, ranked 43rd, with a 55.1% increase and a research and development investment rate of 15.6%, which has gradually approached the average research and development investment rate of 18.2% for the top 50 companies, reaching the 15% threshold for innovative pharmaceutical companies. Ipson rose 21.8 per cent and research and development investment was 15.1 per cent. The biggest decline in research and development spending was in Israel's Teva Pharmaceuticals, down 16.7 per cent and research and development investment at 9.1 per cent, which is estimated to be linked to its business consolidation woes. The only company on the list with a research and development investment rate of more than 50%, is the 31st-ranked Regenerative Yuan Pharmaceuticals, which has reached an incredible 53.9%, which has exceeded 53% for the second year in a row. Fortescue Pharmaceuticals has the highest investment rate of 33.5 percent. In addition, Lilly, Otsuka, UCB, and Acropolis have a research and development investment rate of more than 25.0%. Yunnan White Medicine, which is listed, is bottom with $25 million in research and development and 0.58% of research and development.
this ranking is based on the 2019 sales data of major pharmaceutical companies, the Annual List of Pharmaceutical Managers is from the global pharmaceutical market research institute Evaluate Pharm, which focuses on prescription drug sales by pharmaceutical companies around the world, and the sales data reflect global sales of human-made pharmaceutical preparations and vaccines, without taking into account the revenue from veterinary drugs and consumer health products, and the sales revenue of OTC drugs is as excluded as possible. So.